Bone grafting is a surgical procedures which includes replacement of missing bone. Different types of bone grafts such as autologous bone graft, allograft, and synthetic bone graft are used in bone grafting procedures. Increasing adoption of bone graft substitutes such as ceramics, polymers, bioactive glass, and others are expected to drive the market growth over the forecast period. Technological advancements in implementation of human growth factors into bone grafts that has osteoconductive and osteoinductive properties such as demineralized bone matrix, bone morphogenetic proteins, and platelet rich plasma (PRP), are expected to offer growth opportunities for market players to establish a strong position in the global bone graft and substitutes market over the forecast period.

Researchers are focused on developing innovative bone grafts for treating bone related disorders. For instance, in 2015, scientists at the Texas A&M University, developed a new synthetic material- a biodegradable scaffold to fill the gaps for new bone growth to advance grafting treatments required by the people for treating bone defects and bone cancers.

Increasing prevalence of bone cancer is expected to drive global bone graft and substitutes market growth

Rising prevalence of bone cancer is expected to fuel demand for bone grafts and substitutes thereby supporting the global bone graft and substitutes market growth over the forecast period. For instance, according to 2017 American Society of Clinical Oncology (ASCO) estimates, around 3,450 people of all ages in the U.S. were diagnosed with primary bone cancer. Thus, new cases of bone cancer are expected to propel growth of the bone cancer treatment market in the U.S.

Furthermore, key players are focused on strategies such as acquisitions is expected to drive the global bone graft and substitutes market growth over the forecast period. For instance, Kuros Biosciences acquired Xpand Biotechnology in 2016, as a share swapping deal, wherein Kuros used Xpand’s granular formulation ‘MagnetOs’, in order to prepare novel dental bone grafts. With this acquisition, Kuros has anticipated to make significant sales in Europe, American states, and other regions.

Global Bone Graft and Substitutes Market- Restraints

Bone grafting surgeries have provided life-sustaining options to large number of patients suffering from various bone issues, however, the risks associated with surgery failure and graft failure are expected to hamper the market growth over the forecast period. For instance, according to Dental-Implants-01, the dental bone graft failure rates range from 5-10% on an average, as a result of infections and improper stabilization of the grafts. Thus, the failure of implantation is expected to hinder growth of the global bone graft and substitutes market over the forecast period.

Global Bone Graft and Substitutes Market- Regional Analysis

Regional segmentation of the global bone graft and substitutes market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold a dominant position in the global bone graft and substitutes market over the forecast period, owing to factors such as advancements in the field of bone grafting technology and bone graft and substitutes by the key players in the region. For instance, the U.S-based Artoss, Inc. incorporated nano-biology and nanotechnology while manufacturing artificial bone grafts. The company launched NanoBone granules in 2015, followed by NanoBone SFX putty in 2016. Moreover, Thermo Fisher Scientific Inc., EverlyWell, Inc., Lactation Lab, and OmegaQuant, LLC are some of the U.S.-based companies that offer various types of bone graft and substitutes market in the region.

Moreover, Europe is expected to witness significant growth in the global bone graft and substitutes market over the forecast period, owing to rising number of implant procedures performed in the European countries that are expected to drive demand for bone graft and substitutes in Europe. For instance, according to Meddevicetracker, over 56,000 shoulder arthroplasty surgeries were performed in Europe in 2015. New generation implants such as bone grafts have demonstrated improved clinical outcomes thereby reducing the complications.

Furthermore, Asia Pacific is expected to witness significant global bone graft and substitutes market growth, owing to increasing initiatives by Asia Pacific countries such as China, Japan and India in the development of innovative products of bone graft and its substitutes. For instance, the National Chemical Laboratory, Pune (India) developed two new bone graft substitutes PoroSyn and SynOst (bioactive synthetic bone graft granules and putty) in May 2017 that aims to augment and regenerate the bones lost during an accident, disease or injury.

Global Bone Graft and Substitutes Market- Competitive Landscape

Key players operating in the global bone graft and substitutes market include Ace Surgical Supply Co., Inc., NovaBone Product, LLC., Exactech, Inc., Medtronic Plc., LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation., BioHorizons Implant Systems, Inc., Globus Medical, Inc., RTI Surgical, Inc., Geistlich Pharma, Megagen, Novadip Biosciences, Mesoblast Ltd., Alphatec Spine, Inc., Institut Straumann AG, NuVasive, Inc., OsteoMed LLC, KYERON Medical Innovations, ORTHOFIX INTERNATIONAL N.V., Johnson & Johnson, Bone Therapeutics SA, K2M Group Holdings, Inc., and OsteoNovus

Key Developments

In March 2019, Bioventus, launched OSTEOAMP SELECT Fiber, allograft substitutes for the bone injury of spine, foot & ankle etc. OSTEOAMP SELECT Fibers are designed in such a way that they retain the necessary growth factors that supports the bone and they also provide channel for cell migration. During the trauma, the bones may break and may form a void. Thus to fuse such bones OSTEOAMP SELECT Fibers can be used.
In February 2019, Medtronic launched Grafton, which is a Demineralized Bone Matrix (DBM) and is used for bones of spine and can be used for orthopedic procedures. Grafton, has high osteoinductivity, a crucial factor for bone fusion. This product is used as bone graft extender, substitute, and for filling the voids of the skeletal system.
In 2018, Baxter International Inc., received U.S. Food and Drug Administration (U.S. FDA) approval for the Actifuse Flow which is a bone graft substitute, which can be used in orthopedic operative procedures. The product offers faster bone growth in the packaged delivery injection for the insertion of the graft substitute precisely into small bony voids or gaps in the affected bones.
In 2017, NovaBone Products Pvt Ltd., launched two products, NovaBone IRM and the IRM MacroPOR to its collection for bone graft substitutes. The two new products promote osteoblastic and osteogenesis activity wherever they are used as bone graft substitutes.
In 2017, Citagenix, Inc., launched PentOS OI Max, a new bone graft substitute for the purpose of oral and maxillofacial surgery, thus, escalating its line of PentOS OI bone grafts. The product consist of an inductive collagen matrix, which can be combined with stem cells and blood components which are derived from patients.
In 2017, Anika Therapeutics, Inc., received 510(k) clearance from the S. Food and Drug Administration(U.S. FDA) for its hyaluronic acid bone void filler and is specifically used for correcting the defects of skeletal system. The bone void filler, is composed of a synthetic and bone graft substitute made of biocompatible material, is placed into a void, which solidifies at body temperature, and is then during the healing process, it is resorbed and then replaced by the new bone growth.

Global Bone Graft and Substitutes Market Taxonomy

By Product Type